HEMOSENSE INC 4
4 · HEMOSENSE INC · Filed Jul 6, 2005
Insider Transaction Report
Form 4
ULRICH ROBERT D
Director
Transactions
- Conversion
Series C-3 Preferred Stock
2005-07-01−1,664,528→ 0 total(indirect: By Vanguard V, L.P.)→ Common Stock (416,130 underlying) - Conversion
Common Stock
2005-07-01+699,357→ 699,357 total(indirect: By Vanguard V, L.P.) - Conversion
Series B-3 Preferred Stock
2005-07-01−632,911→ 0 total(indirect: By Vanguard V, L.P.)→ Common Stock (158,227 underlying) - Conversion
Series A-3 Preferred Stock
2005-07-01−500,000→ 0 total(indirect: By Vanguard V, L.P.)→ Common Stock (125,000 underlying)
Footnotes (4)
- [F1]Not applicable.
- [F2]Each share of Series A-3, B-3 and C-3 Preferred Stock converted into Common Stock on a 1-for-4 basis immediately prior to the closing of the issuer's initial public offering.
- [F3]Immediately.
- [F4]Dr. Ulrich is a member of Vanguard V Venture Partners, LLC, the general partner of Vanguard V, L.P. Dr. Ulrich disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.